Viewing Study NCT06161532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:43 PM
Ignite Modification Date: 2026-01-01 @ 11:59 AM
Study NCT ID: NCT06161532
Status: RECRUITING
Last Update Posted: 2025-11-26
First Post: 2023-12-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Small Cell Carcinoma of the Bladder View
None Small Cell Carcinoma of the Urinary Tract View
None Squamous Cell Carcinoma of the Bladder View
None Squamous Cell Carcinoma of the Urinary Tract View
None Primary Adenocarcinoma of the Bladder View
None Primary Adenocarcinoma of the Urinary Tract View
None Renal Medullary Carcinoma View
None Squamous Cell Carcinoma of the Penis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Urothelial carcinoma View
None Trophoblastic cell surface antigen 2 View
None Programmed death-ligand 1 View
None SN-38 View
None Immunotherapy View